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ABSTRACT
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease 
characterized by the clonal expansion of malignant B cells. To predict the clinical course 
of the disease, the identification of diagnostic biomarkers is urgently needed. Aberrant 
methylation patterns may predict CLL development and its course, being very early 
changes during carcinogenesis. Our aim was to identify CLL specific methylation patterns 
and to evaluate whether methylation aberrations in selected genes are associated with 
changes in gene expression. Here, by performing a genome-wide methylation analysis, 
we identified several CLL-specific methylation alterations. We focused on the most 
altered one, at a CpG island located in the body of SHANK1 gene, in our CLL cases 
compared to healthy controls. This methylation alteration was successfully validated 
in a larger cohort including 139 CLL and 20 control in silico samples. We also found a 
positive correlation between SHANK1 methylation level and absolute lymphocyte count, 
in particular CD19+ B cells, in CLL patients. Moreover, we were able to detect gains of 
methylation at SHANK1 in blood samples collected years prior to diagnosis. Overall, our 
results suggest methylation alteration at this SHANK1 CpG island as a biomarker for risk 
and diagnosis of CLL, and also in the personalized quantification of tumor aggressiveness.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL), one of 
the most common mature B cell neoplasm subtypes, 
is characterized by the monoclonal expansion of 
malignant B cells. CLL is a clinically and biologically 
heterogeneous disease. In fact, while some patients 
exhibit slow progression of the disease, others experience 
a more aggressive form and require adequate therapy to 
be initiated soon after diagnosis. No screening tests are 
currently recommended for this disease, and CLL is often 
diagnosed when undergoing blood tests for other reasons. 
The two staging systems currently used, Rai and Binet, 
remain good indicators of survival, but do not take into 
account other biological factors implied in the disease 
course, and consequently do not allow early recognition 
of the aggressive forms of the disease [1]. To date, several 
recurrent genomic aberrations, such as del(17p), del(11q), 
trisomy 12, and del(13q), and genetic alterations, such 
as TP53, BIRC3, NOTCH1, SF3B1, have been proposed 
as prognostic biomarkers of CLL cases [2], and their 
characterization is recommended before initiating 
therapeutic treatment. However, since genetic aberrations 
might not be present at diagnosis, and they might occur 
later during the disease course, their characterization is 
not always sufficient to predict the clinical outcome in 
the initial stage. The mutational status of IGHV gene is 
one of the most commonly used prognostic biomarkers 
but, alone, it is inadequate to explain the clinical course 
heterogeneity of this disease. Therefore, diagnostic 
biomarkers and prognostic biomarkers characterizing 
different clinical courses in the early stages of the disease 
are urgently needed.
Aberrant methylation patterns, which represent a 
molecular hallmark of cancer, are early events in tumor 
development, and they might represent early diagnostic 
biomarkers. It has been shown that methylome alterations 
would predict the diagnosis several years prior to the 
clinical appearance of the disease, thus proving to be 
potential markers for carrying out large-scale screening 
tests [3, 4]. Besides, aberrant methylation changes 
might represent a specific signature of different types 
of leukemia, depending on the originating cell [5]. Our 
aim was to identify specific-CLL methylation patterns by 
conducting a genome-wide methylation analysis, and to 
evaluate whether methylation aberrations in selected genes 
are associated with changes in gene expression.
RESULTS
Differential methylation analyses
We conducted a first differential methylation 
analysis between 18 CLL cases and 6 population controls 
(Figure 1A), identifying 5001 CpG sites differentially 
methylated (adjusted p-value <0.05). As expected, the 
CLL methylome was characterized by a widespread 
hypomethylation, but by restricting the analysis to the 
regulatory regions, a switch towards hypermethylation, 
especially in the CpG islands (CGIs), was evident 
Figure 1: Study workflow including description of sample datasets used in the current study. (A) Discovery datasets: CLL, 
MBCN and normal samples for methylation and gene expression studies; (B) Validation datasets: CLL and normal samples analyzed to 
validate our finding. Abbreviations: CLL: chronic lymphocytic leukemia; MBCN: mature B-cell neoplasm; U-CLL: unmutated chronic 
lymphocytic leukemia.
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(Figure 2). Since the genome-wide methylation analysis 
was conducted on whole blood samples, which are 
characterized by a high level of cellular heterogeneity, 
we were not able to detect CpG islands significantly 
(adjusted p-value <0.05) hypermethylated in CLL samples 
compared to normal control samples. For this reason, we 
selected the 100 top-ranked differentially methylated CGIs 
(Supplementary Table 1).
As the total number of lymphocytes is much higher 
in tumor samples than in control samples, it must be taken 
into account in the differential methylation analysis. 
For this reason, we repeated the differential methylation 
analysis using the absolute lymphocyte count data as a 
covariate in the limma model. This analysis identified 
7886 CpG sites differentially methylated (adjusted 
p-value <0.05) between CLL and control samples. There 
was no substantial change in the list of the 100-top ranked 
differentially methylated CGIs (Supplementary Table 1) 
detected in this second analysis, which indicates that the 
differences in the DNA methylation pattern we observed 
between CLL cases and controls were not due to the 
different number of circulating lymphocytes.
SHANK1 methylation alteration as a potential 
tumor biomarker
In order to be able to subsequently carry out a 
functional study, and having little material available, 
we focused our attention on the most altered CGI, 
located in the gene body of SHANK1 (chr19:51198143-
51198460, referred to hg19 assembly). This CGI was 
hypermethylated in the CLL samples, and it showed 
the highest mean differential methylation value 
(Δβ = 0.29) between CLL and control samples (Table 1 
and Supplementary Table 1).
Figure 2: RnBeads differential methylation analysis for tiling, genes, promoters and CpG islands. Each dot represents the 
average beta value for each CpG locus in the region, resulting from the average of the samples belonging to that group. Red dots indicate 
CpG loci significantly differentially methylated between the two groups.
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We conducted a correlation analysis between the 
methylation percentage and the absolute lymphocyte 
count revealing a significant positive correlation (r = 0.78, 
p-value = 0.0045) (Figure 3A) between the two variables.
Since this methylation alteration was detected 
analyzing whole blood samples and a differential cell 
type content has an effect on DNA methylation profile, 
we investigated cell type heterogeneity in our samples. 
The relative contributions of each principal immune 
components of whole blood (B cells, granulocytes, 
monocytes, NK cells, and T cells subsets) in each sample 
were estimated by applying the algorithm of Houseman 
et al. [6] based on the distinctive methylation profiles of 
each cell type.
As expected, granulocytes, the most abundant 
leukocytes in peripheral blood in a healthy condition [7], 
contributed for most of cell type composition in normal 
blood control samples (data not shown).
On the other hand, tumor samples with a high 
lymphocyte count, showed a high CD19+ B-cells 
contribution and higher SHANK1 methylation values, 
compared to samples with low CD19+ B-cells contribution 
(Table 2). Correlation analysis confirmed that there was 
a strong positive correlation between CD19+ B-cells 
Table 1: SHANK1 differential methylation data in the datasets analyzed
Groups Mean Δβ p-value adj p-value
18 CLLs vs 6 normal controls (experimental dataset) 0.29 0.0023 0.2641
139 CLLs vs 20 normal controls (validation dataset) [6] 0.26 8.66e-12 2.43e-10
59 U-CLL vs 6 CD5+NBC/NBC (validation dataset) [8] 0.38 FDR<0.05 [8]
82 CLL/SLL yr before diagnosis vs matched controls 
(experimental predictive dataset) 0.047 0.00863 0.0921
438 MBCN cases yr before diagnosis vs matched controls 
(experimental predictive dataset) 0.03 4.97e-07 7.47e-05
Adj: adjusted; CLL: chronic lymphocytic leukemia; NBC: naïve B cells; SLL: small lymphocytic lymphoma; yr: years; 
MBCN: mature B-cell neoplasms
Figure 3: Correlation analyses between two variables. (A) Correlation analysis between methylation percentage and absolute 
lymphocyte count. SHANK1 methylation values (%) are plotted against absolute lymphocyte count values. Pearson correlation coefficient 
(r) shows a significant positive correlation (r = 0.78, p-value = 0.0045); (B) Correlation analysis between methylation percentage and 
CD19+ B-cells. SHANK1 methylation values (%) are plotted against CD19+ cells contribution values. Pearson correlation coefficient (r) 
shows a significant positive correlation (r = 0.91, p-value = 6,00e-08).
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contribution and SHANK1 methylation values (r = 0.91, 
p-value = 6,00e-08) (Figure 3B).
Individual characteristics such as smoking status, 
age and BMI can affect DNA methylation and should be 
used for adjustment in differential methylation analysis. 
Since our sample size was small, we did not perform an 
adjustment of SHANK1 methylation values using these 
data. However, it can be observed that differences in 
SHANK1 methylation values in cases and between cases 
and controls are not associated to differences in smoking 
status, age or BMI (Table 3).
To validate and increase the robustness of our data, 
we analyzed the methylation data for this CGI, obtained 
by Kulis et al. [8], of 139 CLLs (≥95% neoplastic cells) 
and 20 non-tumoral samples (normal B-cells from 
peripheral blood including total B cells and various 
subtypes of B-cells) (Figure 1B). Methylation data were 
retrieved from the ICGC Data Portal (https://dcc.icgc.org), 
DCC Data Release 27, DCC Project Code: CLLE-ES. We 
detected a Δβ value of 0.26 (p-value = 8.66e-12, adjusted 
p-value = 2.43e-10), confirming SHANK1 
hypermethylation in CLL (Table 1).
In addition, Kulis et al. identified the same CGI 
as hypermethylated in a subgroup of 59 CLL with a low 
or absent IGHV mutational load (U-CLLs) compared to 
6 naïve B cells (CD5+NBC/NBC) (false discovery rate 
<0.05) [8] (Figure 1B, Table 1).
To evaluate the potential role of SHANK1-associated 
CGI as a potential predictive biomarker, we conducted 
a differential methylation analysis between cases and 
matched controls in blood collected at baseline entry into 
the prospective cohort study (Figure 1A), finding a gain 
of methylation in the SHANK1 CGI (chr19:51198143-
51198460) detectable in blood samples collected years before 
diagnosis of 82 CLL and small lymphocytic lymphoma 
(SLL) (Δβ = 0.047, p = 0.00863, adjusted p-value = 0,0921) 
(Table 1). Moreover, by extending the methylation analysis 
to the larger series of 438 mature B-cell neoplasms (MBCN) 
cases, including the 82 CLL/SLL, we confirmed significant 
differential methylation of the same CGI (Δβ = 0.03, p-value 
< 10-7, adjusted p-value = 7.47e-05) between cases and 
controls (Table 1). Figure 4 shows the methylation values 
observed in the extended cohort (Figure 4A) and in the CLL/
SLL subgroup (Figure 4B).
Table 2: Comparison between estimated relative leucocyte contributions, lymphocyte count and SHANK1 
methylation values in CLL samples
Sample ID CD14+ 
monocytes
CD19+ 
B cells
CD4+ T 
cells
CD56+ 
NK cells
CD8+ T 
cells
Granulocytes Lymphocyte 
count/mm3
SHANK1 
Methylation 
value (%)
304012_002 0,104 0,609 -0,010 0,001 0,000 0,245 NA 59
304012_007 0,076 0,114 -0,001 0,011 0,000 0,797 5050 23
304012_030 0,061 0,556 0,000 0,040 0,000 0,355 32380 51
304012_048 0,074 0,693 0,000 0,049 0,000 0,122 9580 57
304032_083 0,084 0,837 0,038 0,000 0,000 0,002 NA 75
304012_088 0,062 0,621 -0,008 0,050 0,000 0,289 45330 63
304012_092 0,099 0,562 0,000 0,146 0,000 0,154 21830 32
304032_100 0,061 0,506 0,000 0,150 0,000 0,323 NA 59
304032_104 0,019 0,323 0,002 0,323 0,000 0,313 NA 31
304012_112 0,073 0,314 0,000 0,056 0,000 0,627 5270 27
304012_114 0,057 0,594 0,000 0,092 -0,001 0,291 24360 36
304032_132 0,000 0,000 -0,016 0,000 0,000 0,988 NA 6
304032_134 0,070 0,185 0,000 0,049 0,000 0,720 NA 12
304012_188 0,089 0,318 0,000 0,104 0,000 0,484 5410 16
304012_193 0,047 0,890 -0,028 0,000 -0,006 0,015 58880 69
304012_196 0,090 0,342 0,000 0,099 0,000 0,549 9060 44
304012_198 0,065 0,042 0,096 0,157 0,000 0,672 NA 10
304012_475 0,068 0,821 0,000 0,001 0,000 0,000 94100 69
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Table 3: Clinical and immunophenotypic characteristics of the samples used for methylome analysis
Clinical and immunophenotypic characteristics
CLL 
patients
Sample 
ID Age Sex
Smoking 
status BMI CD5+ (%)
CD5+/
CD19+ 
(%)
CD23+ (%) CD38+ (%)
IGHV 
mutational 
status
Lymphocyte 
count/mm3
SHANK1 
Methylation 
value (%)
304012 
002 67 M
No 
Smoker 19,6 NA NA NA NA NA NA 59
304012 
007 81 M
No 
Smoker 23,8 93.30 71.50 72.10 42 Positive 5050 23
304012 
030 67 M
No 
Smoker 27,2 98.60 92 92 2.6 Negative 32380 51
304012 
048 64 F
No 
Smoker 26,7 94.1 78.70 75.40 15 Negative 9580 57
304032 
083 75 M Smoker 32,9 NA NA NA NA NA NA 75
304012 
088 79 M
No 
Smoker 33,8 98.2 91 91.4 4.7 Negative 45330 63
304012 
092 64 M
No 
Smoker 26,9 88.7 64.8 63.7 10 Positive 21830 32
304012 
112 83 F
No 
Smoker NA 34 6 70.3 14 Negative 5270 27
304012 
114 73 M
No 
Smoker 25,5
Negative/ 
weak NA 65 16 Negative 24360 36
304012 
188 43 F
No 
Smoker 21,0 97 87 88 9 Positive 5410 16
304012 
193 52 M Smoker 30,8 56 NA NA NA Negative 58880 69
304012 
196 58 F
No 
Smoker 18,6 68 54 76 NA Negative 9060 44
304012 
198 48 F
No 
Smoker 21,9 NA NA NA NA NA NA 10
304012 
475* 60 M
No 
Smoker 23,0 97.9 94.60
Partially 
expressed Weak Positive 94100 69
Controls
304012 
357 37 F
No 
Smoker 24,7 – – – – – – 9
304012 
368 68 M
No 
Smoker 30,8 – – – – – – 10
304012 
427 47 M
No 
Smoker 26,8 – – – – – – 10
304012 
429 69 M
No 
Smoker 28,1 – – – – – – 13
304012 
448 67 F
No 
Smoker 21,7 – – – – – – 16
304012 
455 20 M Smoker 21,7 – – – – – – 8
For 4/18 patients with CLL diagnosis used for methylome analysis, clinical and immunophenotypic characteristics were not 
available. * this patient was firstly diagnosed as Follicular lymphoma.
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SHANK1 gene expression analysis
To investigate the impact of SHANK1-associated 
CGI hypermethylation on gene expression, we tested the 
gene expression level of SHANK1 in 27 CLL cases and 16 
non-tumor subjects by qRT-PCR (Figure 1A). SHANK1 
showed a significant almost 8-fold down-regulation 
(p-value <0.0001) in CLL cases compared to controls 
(Figure 5).
SHANK1 downregulation was also confirmed using 
GUSB as reference gene in a subgroup of samples (data 
not shown).
To validate SHANK1 downregulation observed in 
our CLL samples, we analyzed RNA-seq data publicly 
available. Differential gene expression data of ten CLL 
specimens versus five normal peripheral blood CD19+ 
B cells were retrieved from GEO database under the 
accession number GSE70830. In this dataset, SHANK1 
gene showed a non-significant differential expression 
between CLL and control samples.
Gene expression data of a large dataset [9] 
including 98 CLL and three subtypes of normal B cells 
(naïve, memory IgM/IgD, and memory IgG/IgA), from 
three different healthy individuals revealed that only 
three CLL samples show more than 10 reads and most 
CLL and normal samples have zero reads, therefore 
making these data unsuitable for a validation of SHANK1 
downregulation.
Whole blood gene expression data from The 
Genotype-Tissue Expression (GTEx) Portal (https://
gtexportal.org) revealed that SHANK1 is weakly expressed 
in whole blood (median Transcripts Per Kilobase Million 
(TPM): 0.030, number of samples: 407). RT-qPCR 
represents the most precise and sensitive method to detect 
differences in gene expression for weakly expressed 
genes. On the other hand, the accurate quantification of 
gene expression by RNA seq depends on the sequencing 
depth and it has been suggested that sequencing up to 100 
million reads can be necessary to quantify precisely genes 
and transcripts that have low expression levels [10].
DISCUSSION
Aberrant methylation patterns, one of the most 
striking features of cancer, might represent useful 
biomarkers for prediction of cancer risk, early diagnosis, 
prognosis, and for prediction of response to treatment and 
cancer relapse. Furthermore, as DNA methylation is an 
early epigenetic reversible modification, specific drugs 
can be developed to restore the DNA methylation pattern 
of normal cells at the initial stages of carcinogenesis.
A substantial body of evidence suggests methylation 
changes as innovative biomarkers for both early cancer 
diagnosis and prognosis [11]. Some such changes have 
already shown clinical relevance, such as BRCA1 in 
breast cancer, MGMT in glioblastoma multiform, and 
SEPT9, which has been approved by the Food and Drug 
Administration (FDA) for the diagnosis of colon cancer. 
Since global DNA methylation is similar in resting and 
proliferative compartments [12], aberrant methylation 
patterns may be an early event in CLL, as suggested by 
its occurrence in blood samples collected years before 
diagnosis of mature B-cells neoplasm [3] and CLL [4].
In addition, methylation alterations in CLL, such 
as ZAP70 [13] and HOXA4 [14], have been proposed as 
prognostic biomarker, and differential methylation profiles 
are used to classify CLL patients in three molecular 
CLL subtypes having different clinical features and 
deriving from B-cell subpopulations at different stages of 
differentiation [5,15,16]. To our knowledge, biomarkers 
for detecting CLL at an early stage, which would permit 
the initiation of therapy in the first phases of the disease, 
are still lacking. In our study, we identified several CGIs 
differentially methylated (Supplementary Table 1), and 
we confirmed a genome-wide hypomethylation in CLL 
(Figure 2), as previously observed in other studies [8].
Although three CGIs resulted significantly 
hypomethylated in CLL samples (Supplementary Table 
1), we do not suggest these alterations as diagnostic 
biomarkers since the difficulty of setting cut-off values 
to consider a sample as hypomethylated, especially when 
we want to look for an alteration that correlates, as in our 
case, with the number of tumor cells, then a biomarker 
that increases with the increase of tumor cells number. 
On the other hand, hypermethylated CGI showing high 
methylation values in tumoral samples could be more 
easily employed as tumoral biomarker.
Our most striking finding was the hypermethylation 
of a CGI located in the gene body of SHANK1 in CLL 
samples. Although this differential methylation was 
not statistically significant after correction for multiple 
testing probably due to the fact that the sample size in our 
study was small, we were able to replicate our finding by 
in silico analysis of a larger CLL series [8]. This type of 
approach has proved to be successful in the identification 
of other highly specific and sensitive tumor biomarkers 
[17–20]. Moreover, the robustness of our data was verified 
in different validation and exploratory sets (Table 1). For 
these reasons, it is important to mention that, although we 
are aware of the importance of significance threshold for 
epigenome-wide studies (EWAS) [21], the methylation 
alterations detected are somatic epimutations, and even 
at the onset of the disease, thus the heterogeneity of the 
tumor, and in particular, as in this case, a blood tumor, 
needs to be taken into account. In our previous work [19], 
we have shown that in a heterogeneous tissue, such as 
adenoma, the methylation alterations detected were not 
statistically significant after multiple testing adjustment. 
In contrast, the same methylation alteration detected in 
colorectal carcinomas resist to any correction for multiple 
testing. In fact, adenomas include a mixture of cells 
showing methylation alterations and cells not showing the 
Oncotarget4994www.oncotarget.com
alterations compared to colorectal carcinomas where many 
tumor cells present the epimutations.
In silico replication of our result analyzing data 
including CLL samples with ≥95% neoplastic cells and 
control normal B cells [8], confirmed that the detected 
SHANK1 methylation alteration belongs to neoplastic 
cells. The fact that we were able to detect this methylation 
alteration in CLL whole blood samples supported its 
Figure 4: SHANK1 methylation values in 438 MBCN cases/controls and the 82 CLL/SLL cases and controls. (A) Jitter 
plot showing methylation values (Y-axis) in all cases and their matched controls; (B) Jitter plot showing methylation values (Y-axis) in CLL 
cases and their matched controls.
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potential use as a diagnostic biomarker to be introduced 
in clinical practice without the need of performing an 
expensive method such as cell sorting. Interestingly, Kulis 
et al [8] have shown that, in a differential methylation 
analysis between U-CLL samples and naïve B cells of 
control samples, the same SHANK1 CGI, identified as 
altered in our study, was significantly hypermethylated in 
U-CLL. IGHV mutational status is a prognostic biomarker 
in CLL: while patients with a high level of IGHV mutation 
(called as M-CLL) have a favorable prognosis, U-CLL is 
usually associated with poor outcomes. In our case series, 
patients with IGHV mutations had an average SHANK1 
CGI methylation value of 35.0%, while it was 49.6 % in 
IGHV non-mutated patients (Table 3). Also, removing an 
outlier (69.0% methylation), probably due to the fact that 
this patient was first diagnosed with Follicular lymphoma, 
resulted in the methylation average dropping to 23.7%. 
Thus, SHANK1 methylation might be correlated with 
clinical outcomes in CLL. In this regard, it is interesting to 
note that we also observed that the β value for the altered 
CGI in SHANK1 correlates positively with the peripheral 
lymphocyte count at diagnosis (Figure 3), which also 
prompted us to repeat the differential methylation analysis 
by including the lymphocyte count as a covariate; this 
second analysis confirmed the same CGIs as the most 
affected by methylation changes (Supplementary Table 
1). Inference of cell type contributions on tumor whole 
blood samples revealed that there was a strong positive 
correlation between CD19+ B-cells contributions and 
SHANK1 methylation values (Table 2). It is estimated that 
the increased number of lymphocytes, that is observed 
in the lymphocyte count at diagnosis, is mainly due 
(> 80%) to the proliferation of neoplastic cells. In fact, in 
an analysis of 110 patients with an absolute lymphocyte 
count of at least 5 x 109/L, Shanafelt et al. have shown 
that monoclonal B-cells were more than 86% of B-cells, 
while polyclonal B-cells represented only a small fraction 
of total B-cells [22]. Therefore, SHANK1 methylation 
might be a useful molecular biomarker in the personalized 
quantification of tumor aggression in CLL.
Aberrant methylation of genes implicated in MBCN 
is detectable in blood samples collected many years before 
diagnosis [3, 4]. We found that within a prospective cohort, 
there was a significant gain of methylation (differential 
methylation of 3%) in the same SHANK1 CGI detectable 
in peripheral blood collected many years prior to diagnosis 
with MBCN (Figure 4A). In a subgroup of CLL/SLL 
cases within the prospective MBCN cohort, there was an 
even more pronounced gain of methylation (differential 
methylation of 4.7%) compared with matched unaffected 
controls (Figure 4B).
Figure 5: SHANK1 differential gene expression analysis between CLL and control samples. Box plot SHANK1 fold change 
values for CLL and controls samples. *** indicates p-value < 0.0001.
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Since there is an overlap between SHANK1 
methylation levels in cases and controls, SHANK1 cannot 
be suggested as a predictive biomarker at individual 
levels. However, 210/438 (48%) MBCN samples showed 
a differential methylation greater than the average Δβ 
(0.03), ranging from 0.031 to 0.36, and 38/82 (46%) CLL/
SLL samples showed a differential methylation greater 
than the average Δβ (0.047), ranging from 0.06 to 0.33. 
It is important to mention that each case is matched to 
one control. Since we found that SHANK1 methylation 
values are positively correlated to lymphocyte counts 
at diagnosis and patients with poor prognosis according 
to IGHV mutational status showed higher methylation 
values, we can speculate that SHANK1 might be able to 
predict aggressive forms of disease years before diagnosis. 
Further studies including SHANK1 methylation status 
before diagnosis, at diagnosis and follow-up data are 
needed to investigate this hypothesis.
This difference of methylation is in line with, and 
even greater than that observed in other genes years before 
cancer diagnosis [3]. Thus, SHANK1 might be a potential 
predictive biomarker of CLL risk. Although SHANK1 
methylation data at diagnosis in other MBCNs were not 
available in our study, we can speculate that methylation 
of this gene is an early event in leukemogenesis.
The use of an epigenetic biomarker proving to be 
so traceable and informative without cells sorting, is 
particularly useful for preventive purposes. Extensive 
screening aimed to identify individuals at risk for CLL 
would not make much sense using detectors requiring 
cells sorting, while it is possible to find alterations in the 
methylation pattern of this specific CGI already years 
before the onset, starting from whole blood.
SHANK1 is one of the three members of the SHANK 
(SH3 And Multiple Ankyrin Repeat Domains) gene 
family. Their respective proteins, SHANK1, SHANK2 and 
SHANK3 act as scaffold proteins and have a fundamental 
role in the formation, development and function of 
neuronal synapses. Mutations of the SHANK gene family 
are associated to developmental disorders, such as autism 
and schizophrenia. Investigating the association between 
SHANK genes methylation and their expression, Beri 
et al [23] showed that, although all these genes present 
several methylated CpG sites, only SHANK3 was highly 
methylated in tissues where its expression was low or 
absent, suggesting that methylation might regulate tissue-
specific SHANK3 expression.
In our work, the gene expression analysis revealed 
that SHANK1 was significantly down-regulated in CLL. 
The inability to validate this data, in silico, may be due 
to the fact that a gene already normally repressed, if 
further down-regulated, is hardly detectable by means of 
whole exome / whole transcriptome NGS / microarrays 
techniques. It will therefore be important to verify our 
Figure 6: SHANK1 schematic representation. (A) SHANK1 transcripts representation in UCSC Genome Browser. (B) 
SHANK1 protein coding transcripts representation in Ensembl Genome Browser. (C) SHANK1-associated CGI annotation in 
UCSC Genome Browser. The orange box indicates the CGI found altered in our study.
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observation on a larger database, by means of a targeted 
expression study and an ultrasensitive technique such as 
ddPCR. The association between methylation and gene 
expression is very complex and, while hypermethylation 
of CGIs located in gene promoters is usually associated 
with gene down-regulation, hypermethylation of 
intragenic CGIs has been correlated either positively and 
negatively with gene expression [8, 24–27]. Intragenic 
DNA methylation might have a role in several molecular 
processes, such as regulation of cell-context specific 
alternative promoter in gene bodies [28], expression of 
intragenic non-coding RNA [29–32] and transposable 
elements [33], alternative splicing [34], alternative 
polyadenylation sites [35], and enhancer activation [36, 
37]. It has also been shown that intragenic nucleosomes 
with H3K36 trimethylation (H3K36me3), a histone 
modification associated with transcript elongation, recruit 
DNA methyltransferases [38], suggesting that DNA 
methylation is unable to block transcript elongation. In 
CLL, Kulis et al [8], have shown that, in absence of CGI-
promoter methylation, methylation of CpGs located in 
the gene bodies of around 900 genes shows a significant 
correlation (either positive or negative) with gene 
expression.
Since methylation of intragenic CGIs might be 
inversely correlated with the expression of an alternative 
transcript and positively regulated with the expression 
of the main transcript [39], it would be interesting to 
investigate the association between the methylation 
of the intragenic CGI of SHANK1 and the expression 
of alternative transcripts. SHANK1, like the other two 
SHANK genes, SHANK2 and SHANK3, presents a 
complex transcriptional structure. This gene contains two 
different promoters, which generate the longest protein 
isoform (called SHANK1A) and the shortest one (called 
SHANK1B), and several splicing sites generating alterative 
transcripts (Figure 6). SHANK1 is mainly expressed in the 
brain (https://www.gtexportal.org/home/gene/SHANK1). 
The CGI found to be hypermethylated in our CLL 
cases is located in the gene body of the main transcript 
(uc002psx.1 or ENST00000293441), but it is upstream of 
the shorter transcript (uc002psw.1 or ENST00000391813) 
(Figure 6). Thus, we speculate that the hypermethylation 
of the intragenic CGI might be associated with a down-
regulation of this shorter transcript. Clearly, a gene 
expression study to accurately quantify each SHANK1 
alternative transcript in a large number of CLL samples 
and controls is warranted to elucidate the impact of this 
intragenic CGI hypermethylation in gene expression 
regulation.
To date, it is difficult to hypothesize whether the 
identified methylation alterations are really associated 
with a different gene expression profile and what this 
may possibly influence from a functional point of view. 
The putative activation or deactivation of isoforms that 
do not respect the normal cell differentiation program 
could obviously affect the cellular functionality, so as to 
induce it to a neoplastic iter. What is certain is that at the 
moment these alterations can provide useful biomarkers 
for the early diagnosis of a neoplasia, as well as, in the 
case of the marker we identified, associate with a different 
prognosis and even giving the possibility of predicting a 
risk of disease onset.
Other SHANK1-associated CGIs are reportedly 
differentially methylated in other cancers, and they have 
been proposed as tumor biomarkers [19, 40]. The most 
plausible scenario would be that methylation changes 
in different SHANK1-associated CGIs would be related 
to different types of cancer, thus serving as specific 
signatures for different types of tumors.
In summary, our results suggest SHANK1 as a 
promising tumor biomarker for CLL early diagnosis. 
Since no screening tests are recommended for CLL 
and patients can be asymptomatic, it is difficult to 
diagnose CLL in the first phases of the disease. The 
introduction of a methylation-based diagnostic biomarker 
in clinical practice could allow an early detection of 
CLL cases and the initiation of adequate therapeutic 
treatments in the first phases of the disease. SHANK1 
hypermethylation can be easily found analyzing whole 
blood samples without cell sorting, supporting its 
utility in clinical practice. Moreover, since SHANK1 
methylation levels correlated with lymphocyte count at 
diagnosis it can be particularly useful in the recognition 
of the most aggressive forms of the disease showing a 
fast progression. Finally, the detection of SHANK1-
associated CGI gain of methylation many years before 
diagnosis suggests that SHANK1 methylation levels may 
be predictive of CLL development. Thus, a screening 
test based on SHANK1 methylation levels assessment 
could be developed to monitor people at risk, such as 
people over age 50, or subjects presenting familiarity 
for the disease. Further studies on sequential samples 
before diagnosis, at diagnosis and during disease course 
are needed to monitor SHANK1 methylation levels and 
ascertain its involvement in CLL progression.
MATERIALS AND METHODS
Tumor specimens
Eighteen Italian patients (10 men and 8 women, 
mean age at diagnosis: 65.3±12.3) with a diagnosis 
of CLL donated a blood sample during their first 
visit at the outpatient ambulatory of the Hematology 
department of the A. Businco Oncology Hospital, 
Cagliari (Sardinia, Italy). All patients were diagnosed 
using the 2008 WHO Classification of lymphoid 
neoplasms criteria. [41]
Blood samples from six controls (mean age: 
51.3±20.2), selected from the 151 participating in a 
population-based case-control study in the same area 
of CLL patients, were included in the genome-wide 
methylation analysis.
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Demographic characteristics (age, sex, smoking 
status and BMI) of CLL patients and controls and clinical 
and immunophenotypic characteristics of CLL samples are 
reported in Table 3.
Mean age (p-value = 0,0711; Student t test), sex 
(p-value = 1,0000; Fisher’s exact test), smoking status 
(p-value = 1,0000; Fisher’s exact test) and mean BMI 
(p-value = 0,9613; Student t test) were not statistically 
significant different between cases and controls.
In addition, blood samples were available for 27 
out of the 29 CLL incident cases (mean age at diagnosis: 
65.1±9.3) recruited for the same study at participating 
Italian hospitals in Novara, Florence, Perugia and 
Cagliari, and for a random sample of 16 out of the 455 
population controls from the same areas, who accepted 
taking part to the full study protocol. We conducted the 
gene expression analysis for these 27 CLL cases and 16 
controls.
We also tested the hypothesis that the selected 
SHANK1 CpG island (CGI) might undergo methylation 
changes prior to the clinical manifestation of the disease 
using a case control study nested within a prospective 
cohort study of 438 samples of incident mature B-cell 
neoplasms (MBCN), including 82 CLL and small 
lymphocytic lymphoma (SLL) cases, considered two 
forms of the same disease only differing by the location 
where the cancer primarily occurs, and matched 
(individually matched to cases at 1:1 ratio based on 
age at enrollment, gender, ethnicity and DNA source) 
controls. Additional information about cases and controls 
demographic characteristics and matching criteria can be 
found in Woong Doo et al. [3]. In this cohort, the mean 
time between blood collection and diagnosis was 9.5 
years (range 0.6-17.8 years) for CLL cases and 10.6 years 
(range 0.2-20 years) for the entire MBCN cohort. DNA 
was collected predominantly from whole blood samples 
and analyzed as previously described. In particular, of 
the 976 samples, 632 were processed from whole blood, 
234 from Ficoll-separated mononuclear cells and 10 from 
buffy coat. [3]
All the biological samples analyzed were obtained 
with written informed consent signed by patients/study 
participants and ethical approval granted by the “Comitato 
Etico Azienda Ospedaliero Universitaria di Cagliari” 
(269/09/CE, 26/05/2009).
DNA and RNA extraction
DNA was isolated from peripheral whole blood 
lymphocytes using the DNA extraction 500 arrow® Kit 
(DiaSorin Ireland Ltd) kit. DNA was quantified with 
NanoDrop (NanoDrop Products Thermo Scientific 
Wilmington, DE) and by fluorometric reading (Quant-
iT™ PicoGreen® dsDNA Assay Kit).
RNA was extracted from PBMCs (Mononuclear 
cell fractions, isolated over a Ficoll-Hypaque density 
gradient) using Qiagen RNAeasy mini kit (Qiagen, 
Hilden, Germany) and quantified using NanoPhotometer 
(NanoPhotometer™Pearl, Denville®, Denville Scientific, 
Holliston, MA).
DNA methylation analysis
The DNA extracted was bisulfite converted using the 
EZ DNA Methylation gold Kit (Zymo Research, Irvine, 
CA, USA) according to manufacturer’s instructions. 
Bisulfite converted DNA was hybridized to Illumina 
Infinium HumanMethylation450 BeadChips (450K), 
following the Illumina Infinium HD Methylation protocol. 
Hybridization fluorescent data were read on an Illumina 
HiScan SQ scanner.
Illumina Methylation 450K raw data were 
analyzed using the RnBeads analysis software package 
as previously described. [42, 43] Methylation levels 
[beta values (β)] were estimated as the ratio of signal 
intensity of the methylated alleles to the sum of 
methylated and unmethylated intensity signals of the 
alleles. The β values ranges from 0 (no methylation) to 
1 (100% methylation).
Differential methylation analysis was conducted 
on the CpG sites and other 4 genomic regions (tailing, 
genes, promoters and CpG Islands, so called CGIs). 
CpG-level p-values were corrected for multiple testing 
using the false discovery rate (FDR) method. CpG-
specific uncorrected p-values within a given genomic 
region were combined to obtain aggregate p-values for 
each genomic region and then corrected for multiple 
testing. [42, 43] Based on the absolute and relative 
effect size of the differences between the study groups, 
RnBeads combines statistical testing with a priority 
ranking scheme to assign a combined rank score for 
differential DNA methylation to each analyzed CpG site 
and genomic region. [42] The generated priority-ranked 
list was used to select the top-100 ranked differentially 
methylated CGIs. The selected CGIs were annotated 
to nearest genes by using R annotation package FDb.
InfiniumMethylation.hg19. [44]
An additional methylome analysis was performed 
adding absolute lymphocyte count data as a covariate 
in the limma analysis of differential DNA methylation. 
[42, 45] DNA methylation analysis for the samples in 
the nested case-control study were also performed on 
the Illumina HM450K Infinium array as previously 
described. [3]
Inference of cell type contributions was conducted 
using RnBeads applying the method of Houseman et al. 
[6]. This method estimated the cell type contributions 
of whole blood samples based on methylation profiles 
of a sorted blood cell types reference. [46] The 
validity of this method for estimating whole blood 
cells composition in CLL samples has been recently 
demonstrated. [4, 47]
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qRT-PCR
1μg RNA/sample was retro-transcribed using 
the High Capacity Kit (Applied Biosystems, Carlsbad, 
CA, USA). Gene expression analysis was performed by 
qRT-PCR, conducted on a DNA Engine Opticon 2 Real-
Time Cycler (Bio-Rad, Hercules, CA, USA), using iQ™ 
SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA) 
for each gene tested and for the reference genes. Actin 
Beta (ACTB) gene, which is one of the most often used 
reference genes in B-CLL gene expression studies [48, 
49], was used as reference gene. A subgroup of tumoral 
and non-tumoral samples was also analyzed using 
Glucuronidase Beta (GUSB) as reference gene.
Primers used in this study to conduct qRT-PCR are 
the following:
- 5’-AGACCATCAGTGCAAGCGAA-3’ (SHANK1 
forward)
- 5’-GGGATCGAAGCTCGACTCAG-3’ (SHANK1 
reverse)
- 5’-AAATCTGGCACCACACCTTC-3’ (ACTB 
forward)
- 5’-AGCACAGCCTGGATAGCAAC-3’ (ACTB 
reverse)
- 5’-CACCTAGAATCTGCTGGCTACT-3’ (GUSB 
forward)
- 5’-AGAGTTGCTCACAAAGGTCACA-3’ 
(GUSB reverse)
Gene expression data were analyzed using the ΔΔCT 
method. We used a t-test for independent series to compare 
the average ΔCT of CLL cases and controls.
Power calculation
The power was estimated using a two-sample t test 
power calculation. A dataset of 18 samples, those available 
to us as discovery set, would guarantee a statistical power 
of 0.8 to detect a differential methylation level of at least 
25%, using a type I error of 10e-8 (which takes into 
account the need to correct for multiple test).
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